Equities research analysts expect Assembly Biosciences Inc (NASDAQ:ASMB) to post $1.68 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Assembly Biosciences’ earnings. The highest sales estimate is $2.66 million and the lowest is $700,000.00. The company is expected to announce its next earnings results on Thursday, March 29th.
On average, analysts expect that Assembly Biosciences will report full-year sales of $1.68 million for the current year, with estimates ranging from $4.40 million to $8.36 million. For the next fiscal year, analysts forecast that the firm will report sales of $7.50 million per share, with estimates ranging from $5.00 million to $10.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Assembly Biosciences.
ASMB has been the subject of several research reports. Zacks Investment Research upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $72.00 price objective for the company in a research report on Tuesday, March 13th. Jefferies Group raised their price objective on shares of Assembly Biosciences to $75.00 and gave the stock a “buy” rating in a research report on Thursday, March 8th. B. Riley initiated coverage on shares of Assembly Biosciences in a research report on Friday, January 5th. They set a “neutral” rating and a $35.00 price objective for the company. BidaskClub upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Tuesday, January 30th. Finally, ValuEngine upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 3rd. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $54.25.
A number of hedge funds have recently modified their holdings of the business. MetLife Investment Advisors LLC acquired a new stake in Assembly Biosciences during the fourth quarter worth approximately $326,000. Endurant Capital Management LP bought a new position in shares of Assembly Biosciences during the fourth quarter worth approximately $430,000. Millennium Management LLC increased its holdings in shares of Assembly Biosciences by 30.4% during the fourth quarter. Millennium Management LLC now owns 133,666 shares of the biopharmaceutical company’s stock worth $6,048,000 after purchasing an additional 31,195 shares during the period. TIAA CREF Investment Management LLC increased its holdings in shares of Assembly Biosciences by 46.8% during the fourth quarter. TIAA CREF Investment Management LLC now owns 72,331 shares of the biopharmaceutical company’s stock worth $3,273,000 after purchasing an additional 23,064 shares during the period. Finally, Teachers Advisors LLC increased its holdings in shares of Assembly Biosciences by 16.1% during the fourth quarter. Teachers Advisors LLC now owns 28,964 shares of the biopharmaceutical company’s stock worth $1,311,000 after purchasing an additional 4,025 shares during the period. Hedge funds and other institutional investors own 76.81% of the company’s stock.
Shares of ASMB stock traded down $2.95 during trading hours on Friday, reaching $55.22. 128,347 shares of the company traded hands, compared to its average volume of 162,032. Assembly Biosciences has a twelve month low of $18.60 and a twelve month high of $67.36. The firm has a market cap of $1,168.50, a P/E ratio of -19.59 and a beta of 0.57.
TRADEMARK VIOLATION NOTICE: “Assembly Biosciences Inc (ASMB) Expected to Announce Quarterly Sales of $1.68 Million” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://stocknewstimes.com/2018/03/23/assembly-biosciences-inc-asmb-expected-to-announce-quarterly-sales-of-1-68-million.html.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.